帕金森病中左旋多巴诱导的运动障碍:一项基于人群的队列研究
该研究利用1991-2010年奥姆斯特德县基于人群的帕金森综合征发病队列(n=669),纳入309例帕金森病患者,其中279例(90.3%)接受左旋多巴治疗。结果显示30.1%的患者出现左旋多巴诱导的运动障碍,中位潜伏期4年,多数为轻度;严重运动障碍占所有左旋多巴治疗患者的3.2%。
要点
- 279例接受左旋多巴治疗的帕金森病患者中,84例(30.1%)出现运动障碍。
- 运动障碍中位出现时间为左旋多巴起始后4年,65.5%在5年内发生。
- 严重运动障碍占所有左旋多巴治疗患者的3.2%,占运动障碍患者的10.7%。
核心结论
- 在本队列中,左旋多巴诱导的运动障碍影响30%的帕金森病患者。
- 梅奥神经科医生倾向于优化左旋多巴剂量治疗大多数患者。
- 运动障碍在所有左旋多巴治疗的帕金森病患者中严重者占3.2%(占所有运动障碍患者的10.7%),接受脑深部电刺激治疗者改善明显。
研究设计与样本
- 基于人群的队列研究,利用罗切斯特流行病学项目获取1991-2010年奥姆斯特德县帕金森综合征发病队列(n=669),识别帕金森病患者并提取左旋多巴相关运动障碍信息。
主要发现
- 309例帕金森病患者中279例(90.3%)接受左旋多巴治疗;230/279(82.4%)曾由梅奥诊所神经科医生治疗。
- 309例帕金森病患者诊断时中位年龄74.1岁(范围33.1-97.8岁),左旋多巴起始中位年龄75岁(范围37-98岁),治疗中位持续时间6年(范围2个月至19.8年)。
- 279例接受左旋多巴治疗的患者中84例(30.1%)记录到运动障碍;从左旋多巴起始至运动障碍出现的中位时间为4年(范围2个月至20年)。
- 84例运动障碍患者中,55例(65.5%)在左旋多巴起始后5年内发生(其中9例在第一年内);严重程度为轻度57/84(67.9%)、中度16/84(19.1%)、重度9/84(10.7%),2例严重程度未报告。
- 运动障碍严重程度导致调整左旋多巴或启用金刚烷胺者占60.7%(51/84),其中23/51(45.1%)改善;13例运动障碍患者接受脑深部电刺激并报告明显改善;7例尸检病例证实路易体病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess dyskinesia frequency in a population-based cohort of patients with Parkinson disease (PD). Dyskinesia complicates levodopa treatment and affects quality of life. METHODS: Utilizing the 1991-2010 population-based, parkinsonism-incident cohort of Olmsted County, MN (n = 669), accessed via the Rochester Epidemiology Project, we identified patients with PD and abstracted levodopa-related dyskinesia information. RESULTS: Of 309 patients with PD (46.2% with parkinsonisms), 279 (90.3%) received levodopa. Most (230/279; 82.4%) had been treated by a Mayo Clinic neurologist. Median age of the 309 patients with PD at the time of diagnosis was 74.1 years (range 33.1-97.8 years). Median-age levodopa initiation in this cohort was 75 years (range 37-98 years), and median-duration levodopa treatment was 6 years (range 2 months to 19.8 years). Dyskinesia was documented in 84 of 279 patients (30.1%). Median time from levodopa initiation to dyskinesia onset was 4 years (range 2 months to 20 years); those with dyskinesia (65.5%; 55/84) developed it within 5 years of levodopa initiation (9 within the first year). Dyskinesia was mild in 57/84 (67.9%), moderate in 16/84 (19.1%), and severe in 9/84 (10.7%); severity was not reported in 2 cases. Dyskinesia severity led to levodopa adjustments or amantadine initiation in 60.7% (51/84 of those with dyskinesia), with improvement in 23/51 (45.1%). Thirteen patients with dyskinesia underwent deep brain stimulation, reporting marked improvement. Postmortem examination confirmed Lewy body disease in 7 autopsied cases. CONCLUSIONS: Levodopa-induced dyskinesia affected 30% of the patients with PD in our cohort. Mayo neurologists favoring levodopa dosage optimization treated most patients. Dyskinesia was severe in 3.2% of all levodopa-treated patients with PD (10.7% of all patients with dyskinesia) with marked improvement among those treated with deep brain stimulation.
引用
- Turcano P, Mielke MM, Bower JH, et al. Levodopa-induced dyskinesia in Parkinson disease: A population-based cohort study. Neurology. 2018. PMID: 30404780. doi:10.1212/WNL.0000000000006643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。